NCT02346721已完成3 期
An Open Label Study of Sofosbuvir/GS-5816 Fixed-Dose Combination in Subjects With Chronic HCV Infection
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 111
- 主要终点
- Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
研究概览
简要总结
The primary objectives of this study are to evaluate the efficacy, safety, and tolerability of treatment with sofosbuvir/velpatasvir (SOF/VEL) in participants with chronic genotype 1, 2, 4, 6 or indeterminate HCV infection who received placebo in the Gilead-sponsored study GS-US-342-1138.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing and able to provide written informed consent
- •Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy
- •Was administered placebo to match SOF/VEL in Gilead study GS-US-342-1138
- •HCV RNA ≥ 10^4 IU/mL at screening
- •Classification as treatment naive or treatment experienced
- •Males and females of childbearing potential who engage in heterosexual intercourse must agree to use protocol specified method(s) of contraception
排除标准
- •Current or prior history of clinically-significant illness (other than HCV) or any other major medical disorder that may interfere with treatment, assessment, or compliance with the protocol; individuals currently under evaluation for a potentially clinically-significant illness (other than HCV) are also excluded.
- •Screening electrocardiogram (ECG) with clinically significant abnormalities
- •Laboratory results outside of acceptable ranges at screening
- •Prior exposure to SOF or other nucleotide analogue HCV NS5B inhibitor or any HCV NS5A inhibitor
- •Infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)
- •Note: Other protocol defined Inclusion/Exclusion criteria may apply.
研究组 & 干预措施
SOF/VEL
Experimental
SOF/VEL for 12 weeks
干预措施: SOF/VEL (Drug)
结局指标
主要结局
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
时间窗: Up to 12 weeks
Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12)
时间窗: Posttreatment Week 12
SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ) 12 weeks following the last dose of study drug.
次要结局
- Percentage of Participants With HCV RNA < LLOQ While on Treatment(Baseline to Week 12)
- Percentage of Participants With Sustained Virologic Response 4 and 24 Weeks After Discontinuation of Therapy (SVR4 and SVR24)(Posttreatment Weeks 4 and 24)
- Percentage of Participants With Virologic Failure(Up to Posttreatment Week 24)
- HCV RNA Change From Baseline(Baseline to Week 12)
研究者
相似试验
进行中（未招募）
1 期
A trial looking at the treatment of SOF/GS-5816 in patients with hepatitis C infectioChronic Hepatitis C Virus InfectionMedDRA version: 18.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-003898-42-ITGilead Sciences, Inc.100
进行中（未招募）
1 期
A trial looking at the treatment of SOF/GS-5816 in patients with hepatitis C infectioEUCTR2014-003898-42-GBGilead Sciences, Inc.111
进行中（未招募）
1 期
A trial looking at the treatment of SOF/GS-5816 in patients with hepatitis C infectioChronic Hepatitis C Virus InfectionMedDRA version: 18.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-003898-42-BEGilead Sciences, Inc.124
进行中（未招募）
1 期
A trial looking at the treatment of SOF/GS-5816 in patients with hepatitis C infectioChronic Hepatitis C Virus InfectionMedDRA version: 18.0Level: PTClassification code 10019744Term: Hepatitis CSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 18.0Level: PTClassification code 10008912Term: Chronic hepatitis CSystem Organ Class: 10021881 - Infections and infestationsEUCTR2014-003898-42-DEGilead Sciences, Inc.124
已完成
2 期
Sofosbuvir Plus Ribavirin, or Ledipasvir/Sofosbuvir in Adults With HCV Infection and Renal InsufficiencyHCV InfectionNCT01958281Gilead Sciences38